Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shin Poong Pharmaceutical Co., Ltd. (019170:KRX), powered by AI.
Shin Poong Pharmaceutical Co., Ltd. is currently trading at ₩11,690. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Shin Poong Pharmaceutical Co., Ltd. on Alpha Lenz.
Shin Poong Pharmaceutical Co., Ltd.'s P/E ratio is -37.4.
“Shin Poong Pharmaceutical Co., Ltd. trades at a P/E of -37.4 (undervalued) with modest ROE of -5.8%.”
Ask for details →Shin Poong Pharmaceutical Co., Ltd. is a South Korean company engaged in the development, manufacturing, and distribution of pharmaceutical products. The company's primary function is to provide effective medical solutions and improve health care access through its diverse range of pharmaceuticals. Shin Poong focuses on the production of drugs across several therapeutic categories, including antibiotics, antivirals, and antimalarials, with notable contributions to combating infectious diseases like malaria. The company is renowned for its commitment to research and innovation, continuously investing in the development of novel treatments. In addition to its pharmaceutical endeavors, Shin Poong has an expanding portfolio in the biotechnology and health supplement sectors. Within the financial markets, Shin Poong Pharmaceutical holds significant influence due to its strategic initiatives in international markets and partnerships that extend its reach beyond South Korea. As one of the key players in the pharmaceutical industry, it plays a crucial role in advancing public health and addressing global medical challenges.
“Shin Poong Pharmaceutical Co., Ltd. trades at a P/E of -37.4 (undervalued) with modest ROE of -5.8%.”
Ask for details →Shin Poong Pharmaceutical Co., Ltd. (ticker: 019170) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 809 employees. Market cap is $612.8B.
The current price is ₩11,690 with a P/E ratio of -37.43x and P/B of 2.24x.
ROE is -5.85% and operating margin is -7.70%. Annual revenue is $221.1B.